How balancing brain energy may open new paths for Parkinson's treatments

Rather than simply trying to speed up or shut down the brain's metabolism, scientists are exploring medicines that can delicately tune this energy system. Researchers are examining existing medicines such as terazosin, which gently supports sugar processing, as well as diabetes therapies such as GLP 1 receptor agonists, which calm inflammation and support overall cellular balance. The goal is to nourish vulnerable neurons with reliable fuel while keeping inflammatory immune cells quiet and calm. This promising avenue of research comes from a detailed review published in September 2026 by a team at Nantong University. The scientists looked at how brain cells switch their energy supply when their standard machinery runs into difficulty. Under normal conditions, brain cells rely on miniature power stations called mitochondria, which cleanly convert nutrients and oxygen into a continuous energy supply. In Parkinson's, these primary power stations struggle to keep up with demand. To survive, the cells turn on an ancient backup mechanism called glycolysis, burning through sugar rapidly without needing oxygen. Running on this emergency setting presents a major dilemma. In the short term, the quick burst of energy keeps vulnerable neurons alive. Over longer periods, however, continuous emergency sugar burning produces harmful byproducts such as methylglyoxal, which damage surrounding proteins and add toxic strain. The entire cellular neighbourhood feels the impact of this metabolic shift. Helpful support cells called astrocytes struggle to deliver steady fuel to neurons, whilst resident immune cells, known as microglia, devour excess sugar to power ongoing inflammation. By developing treatments that gently rebalance how the brain handles sugar, researchers hope to protect vulnerable cells from running out of steam without triggering further damage.